Diajard-MXR

Introduction
Diajard-MXR is an oral diabetes medicine used in Pakistan for the management of type 2 diabetes. It is designed as an extended-release (XR) formulation, which means the medicine is released slowly over time, allowing for steady blood sugar control with fewer daily doses. Doctors prescribe it when lifestyle changes or single therapy are not enough to manage sugar levels.

Composition
Each tablet combines two active ingredients:

• Dapagliflozin – an SGLT2 inhibitor that helps remove excess sugar through urine.

• Metformin (extended-release) – a medicine that reduces sugar production in the liver and improves insulin sensitivity.

Medical Use
Diajard-MXR is prescribed for:

• Type 2 diabetes mellitus in adults

• Patients who do not achieve adequate control with metformin alone

• Those requiring combination therapy to reduce long-term risks of diabetes complications, including heart and kidney problems (when used under supervision)

How to Take
The tablet is taken orally, usually once daily with the evening meal to reduce stomach upset and ensure gradual release. The strength (such as 10/500mg XR or 10/1000mg XR) and dose depend on blood sugar levels and a doctor’s instructions. The tablet should be swallowed whole and not crushed or chewed.

Precautions

• Use only as prescribed by a physician.

• Not suitable for type 1 diabetes or diabetic ketoacidosis.

• Inform your doctor if you have kidney or liver problems, frequent urinary infections, or dehydration risk.

• Pregnant or breastfeeding women should consult their doctor before use.

• Avoid alcohol excess while on this medicine.

• Store in a cool, dry place, away from heat, moisture, and children.

Side Effects
Some patients may experience mild stomach upset, nausea, or diarrhea at the start of therapy, which usually improves with time. Other possible effects include urinary tract infections, increased urination, or headache. Rare but serious risks include dehydration, low blood sugar (if used with other medicines), or lactic acidosis from metformin.

Doctor’s Review
Dr. Salman Tariq – Consultant Endocrinologist

“Diajard-MXR combines dapagliflozin with metformin in an extended-release formulation. This design supports once-daily dosing and may help improve patient comfort and tolerance compared to immediate-release options. The dual action addresses blood glucose control through both improved insulin sensitivity and increased glucose excretion. As with any therapy, consistent monitoring and attention to hydration remain important for safe, long-term use.”

Disclaimer
This information is provided for educational and product knowledge purposes only. It is not a prescription and should not replace professional medical advice. Always consult a qualified healthcare professional before starting or changing any diabetes treatment.